Inveready invests in Iteria Biopharma to accelerate the development of treatments for advanced metastatic cancer — Inveready

Barcelona, May 16, 2026

Inveready, through its vehicle Inveready Biotech IV, has led a €5M Series Seed round in Iteria Biopharma, a Galician biotech company founded in 2024 focused on developing innovative drugs for advanced metastatic cancers. The round also counts on the participation of XesGalicia and the founding partners. The proceeds will fund the regulatory preclinical development and the first Phase 1 clinical trial of ITR-251, a novel compound targeting metastatic prostate cancer resistant to hormonal treatments, alongside two early-stage research programmes in pancreatic, colorectal and lung cancer.